Logotype for OptimizeRx Corporation

OptimizeRx (OPRX) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for OptimizeRx Corporation

Q2 2026 earnings summary

13 Aug, 2026

Executive summary

  • Q2 2026 revenue was $20.5 million, down 30% year-over-year, but both revenue and adjusted EBITDA of $4.9 million exceeded consensus expectations despite declines driven by a small number of large customers and transition away from lower margin managed services.

  • Net revenue declined 21% year-over-year for the six months ended June 30, 2026, primarily due to the loss of a major customer and discontinuation of low-margin managed service programs.

  • Margin expansion and disciplined operational execution drove profitability, with gross margins expected to normalize in the high 60% to low 70% range for the full year.

  • Investments in AI-enabled platform capabilities, new product launches, and expanded programmatic initiatives are strengthening customer engagement and competitive positioning.

  • Leadership transition announced: Andy D'Silva to become CFO in 2027, with Ed Stelmakh remaining as strategic advisor.

Financial highlights

  • Q2 2026 revenue was $20.5 million, down from $29.2 million in Q2 2025; net revenue for H1 2026 was $40.3 million, down from $51.1 million in the prior year period.

  • Net loss of $0.7 million ($0.04 per share) in Q2 2026 vs. net income of $1.5 million ($0.08 per share) in Q2 2025; non-GAAP net income was $3.1 million ($0.16 per share) vs. $3.7 million ($0.19 per share) last year.

  • Adjusted EBITDA was $4.9 million in Q2 2026, down from $5.8 million in Q2 2025.

  • Operating cash flow for H1 2026 was $8.1 million; cash and cash equivalents stood at $24.1 million as of June 30, 2026.

  • Expenses decreased by $5.4 million year-over-year to $20.6 million, including $1.7 million in severance; cost of revenues as a percentage of revenue improved to 24% from 37% year-over-year.

Outlook and guidance

  • Full-year 2026 revenue guidance reaffirmed at $95–$100 million; adjusted EBITDA guidance at $21–$25 million.

  • Revenue expected to be weighted toward the second half, with Q4 likely representing 35–40% of full-year revenues.

  • Management expects macroeconomic headwinds, including inflation, tariffs, and industry-specific challenges, to continue impacting customer spending and revenue visibility over the next twelve months.

  • Profitability and margin improvements are expected to be sustainable, not episodic.

  • Rule of 40 remains a long-term objective, with expectations to return to that threshold in 2027 as growth resumes.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more